Reference ID: 4399464
Spravato, INN-esketamine
SPRAVATO® Efficacy | SPRAVATO® (esketamine) HCP
Clinical trials of Allergan's antidepressant rapastinel fail - MedCity News
SPRAVATO® (esketamine) CIII Treatment Center | Considerations
Approval of esketamine for treatment-resistant depression - The Lancet Psychiatry
SPRAVATO®
Caution urged over use of fast-acting version of ketamine for depression
Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
SPRAVATO® Efficacy | SPRAVATO® (esketamine) HCP
SPRAVATO® Safety & Tolerability | SPRAVATO® (esketamine) HCP
SPRAVATO®
Spravato 28 mg nasal spray, solution - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Concomitant Use of SPRAVATO With Antidepressant Monotherapy or Augmentation Therapy in Clinical Trials in Major Depressive Disorder and Suicidal Ideation with Intent
SPRAVATO®
SPRAVATO® Efficacy | SPRAVATO® (esketamine) HCP
SPRAVATO™ Clinical Studies | Touchstone TMS
Spravato Debate Still Rages | MedPage Today
Intranasal Esketamine - Psychopharmacology and Clinical Application
SPRAVATO® Efficacy | SPRAVATO® (esketamine) HCP
